Composition for Improving Skin Conditions Using Fetal Mesenchymal Stem Cells from Amniotic Fluid

• US 20120141399A1
• Filed: 03/19/2010
• Published: 06/07/2012
• Est. Priority Date: 03/20/2009
• Status: Active Grant

• Current Assignee: Stemmedience Co., Ltd.
• Original Assignee: Stemmedience Co., Ltd.
• Inventors: You, Seungkwon, Yoon, Byung Sun, Lee, Jong Won, Moon, Jai-Hee, Jun, Eun Kyoung, Kim, Jonggun, Jung, Hye-Youn, Lee, Jung Han, Park, Eulsoon, Maeng, Isaac, Kim, Jun Sung, Lee, Jang Ho, Lee, Hwang Heui, Cho, Kyoung Shik
• Granted Patent: US 8,586,540 B2
• Time in Patent Office: Days
• US Class Current: 424/62
• CPC Class Codes: A61K 8/981 of mammals or bird
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61Q 17/04 Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• CPC Class Codes: A61Q 19/02 for chemically bleaching or whitening the skin
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations

Abstract

The present invention relates to a culture medium for the fetus-derived mesenchymal stem cells in amniotic fluid. More particularly, the present invention relates to a composition for improving skin conditions, comprising the culture medium of fetus-derived mesenchymal stem cells in amniotic fluid as an active ingredient, in which the skin conditions to be improved include whitening, wrinkles, skin damages caused by UV rays or skin lifting. Further, the present invention relates to a method for preparing the composition, comprising the steps of culturing the fetus-derived mesenchymal stem cells in amniotic fluid; and collecting the culture medium.

Claims

1. A method for improving skin conditions, comprising applying a culture medium of fetus-derived mesenchymal stem cells in amniotic fluid as an active ingredient, wherein the skin condition is whitening, wrinkles, skin damages caused by UV rays, or skin lifting.

2. The method according to claim 1, wherein the fetus-derived mesenchymal stem cells in amniotic fluid has the following characteristics:

(a) showing the immunological characteristics of being all positive for CD13, CD29 and CD44;

(b) growing and adhering to cell culture plates and showing a spindle-shaped morphology; and

(c) having a capacity to differentiate into mesodermal cell lineages.

3. The method according to claim 1, wherein the culture medium of the fetus-derived mesenchymal stem cells in amniotic fluid comprises Apo-1/Fas, epidermal growth factor (EGF), IP-10(Interferon-γ

inducible protein-10), Leptin, MIP4, MMP3, Rantes, interferon-gamma (IFNγ

), human transforming growth factor (TGF-β

), tumor necrosis factor-alpha (TNFα

), tumor necrosis factor receptor □

(TNFR□

), tumor necrosis factor receptor□

(TNFR□

), intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), vascular endothelial growth factor (VEGF), interleukin-1beta (IL-1β

), interleukin-1 receptor alpha (IL-1Rα

), IL-2, IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-12 and IL-15.

4. The method according to claim 1, wherein the culture medium is contained in a cosmetic composition.

5. The method according to claim 4, wherein the composition has a formulation selected from the group consisting of a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powdered foundation, an emulsion foundation, a wax foundation, and a spray.

6. The method according to claim 1, wherein the culture medium is contained in a pharmaceutical composition.

7. A method for preparing an agent for the improvement of skin conditions comprising culturing the fetus-derived mesenchymal stem cells in amniotic fluid;

and collecting the culture medium, wherein the skin condition is whitening, wrinkles, skin damages caused by UV rays, or skin lifting.

8. The method according to claim 7, comprising:

(a) isolating the fetus-derived cells in amniotic fluid that is obtained from a pregnant woman;

(b) subculturing the cells in a medium supplemented with FBS and bFGF so as to obtain the fetus-derived mesenchymal stem cells in amniotic fluid;

(c) culturing the obtained fetus-derived mesenchymal stem cells in amniotic fluid in a serum-free medium for 1 to 10 days so as to prepare a conditioned medium; and

(d) collecting the conditioned culture medium.